Collaborate on innovative manufacturing platforms and technologies that accelerate the development and manufacture of life-saving medicines and medical countermeasures, enhance national economic security, and support response to biothreats
Help companies de-risk the adoption and implementation of new technologies and approaches for development and manufacturing
Strengthen the U.S. economy by cultivating a world-leading biopharmaceutical workforce that meets the industry’s needs through novel training and education programs
Udit Batra, President & CEO, Waters
We achieve our mission through an RFx process that aims to advance technical and workforce development projects:
Topic: Filtration Practices of mRNA-LNP Drug Products
Submission Deadline: October 1, 2025
NIIMBL is pleased to share this Request for Information (RFI) on filtration solutions for mRNA-LNP drug products.
The goal of this RFI is to gather insights and ideas regarding innovative approaches, current practices, and validation strategies for sterile filtration of lipid nanoparticle (LNP)-based products, including mRNA therapeutics.
We are pleased to announce a new Request for Information (RFI) to gather community engagement for a future interlaboratory study into Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC) Method Harmonization. This RFI supports our Viral Vector Program’s effort to drive innovation in Adeno-Associated Virus (AAV) gene therapy.
The purpose of this RFI is to identify and engage capable parties for participation in a future interlaboratory study and gather community input on the utility of SV-AUC for AAV analysis for therapeutic characterization and/or batch release.
The submission deadline is October 1, 2025 (5 pm ET).
NIIMBL is pleased to issue a Request for Applications (RFA) for the NIIMBL eXperience for Educators Program.
The NIIMBL eXperience for Educators is a one- or two-day immersive event designed to introduce K–12 educators and counselors to the biopharmaceutical manufacturing industry. Through hands-on activities, industry engagement, and networking, participants will gain valuable insights into career opportunities and educational pathways for their students.
The application deadline is October 15, 2025.
RFA: Viral Vectors AAV Testing Methods Evaluation (2025.02)
Submission Deadline: October 21, 2025
NIIMBL is pleased to announce this Request for Application (RFA) to participate in the Viral Vector Program‘s initiative on evaluation of methods for the quality control of adeno-associated virus (AAV) aggregates.
This RFA aims to advance the understanding of AAV vector aggregation by evaluating available analytical techniques for aggregate detection, quantitation, and characterization, resulting in a recommendation on technique(s) suitable for ensuring appropriate product quality for early-stage clinical development. Learnings from the project will be openly shared across the academic, non-profit, and biotech communities that are advancing gene therapy development.
NIIMBL is pleased to announce the pilot of a faculty sabbatical in industry program. The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member (Tier 1 or Tier 2) or at NIIMBL’s Headquarters (NIIMBL HQ) in Delaware to support NIIMBL-led projects.
The NIIMBL Faculty Fellows program closes December 31, 2024.
Concept submissions for Project Call 9.1 are now closed.
NIIMBL is pleased to announce Project Call 9.1, with member- driven and industry-led priority topic areas for technical development proposals.
Technology Topics:
Workforce Development Topics
We achieve our mission through an RFx process that aims to advance technical and workforce development projects:
RFI: Sterile Filtration (2025.001)
Topic: Filtration Practices of mRNA-LNP Drug Products
Submission Deadline: October 1, 2025
NIIMBL is pleased to share this Request for Information (RFI) on filtration solutions for mRNA-LNP drug products.
The goal of this RFI is to gather insights and ideas regarding innovative approaches, current practices, and validation strategies for sterile filtration of lipid nanoparticle (LNP)-based products, including mRNA therapeutics.
RFI: Viral Vectors SV-AUC Method Harmonization Study
We are pleased to announce a new Request for Information (RFI) to gather community engagement for a future interlaboratory study into Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC) Method Harmonization. This RFI supports our Viral Vector Program’s effort to drive innovation in Adeno-Associated Virus (AAV) gene therapy.
The purpose of this RFI is to identify and engage capable parties for participation in a future interlaboratory study and gather community input on the utility of SV-AUC for AAV analysis for therapeutic characterization and/or batch release.
The submission deadline is October 1, 2025 (5 pm ET).
RFA: NIIMBL eXperience for Educators
NIIMBL is pleased to issue a Request for Applications (RFA) for the NIIMBL eXperience for Educators Program.
The NIIMBL eXperience for Educators is a one- or two-day immersive event designed to introduce K–12 educators and counselors to the biopharmaceutical manufacturing industry. Through hands-on activities, industry engagement, and networking, participants will gain valuable insights into career opportunities and educational pathways for their students.
The application deadline is October 15, 2025.
RFA: Viral Vectors AAV Aggregates Testing Method Evaluation
RFA: Viral Vectors AAV Testing Methods Evaluation (2025.02)
Submission Deadline: October 21, 2025
NIIMBL is pleased to announce this Request for Application (RFA) to participate in the Viral Vector Program‘s initiative on evaluation of methods for the quality control of adeno-associated virus (AAV) aggregates.
This RFA aims to advance the understanding of AAV vector aggregation by evaluating available analytical techniques for aggregate detection, quantitation, and characterization, resulting in a recommendation on technique(s) suitable for ensuring appropriate product quality for early-stage clinical development. Learnings from the project will be openly shared across the academic, non-profit, and biotech communities that are advancing gene therapy development.
RFA: Faculty Fellows
NIIMBL is pleased to announce the pilot of a faculty sabbatical in industry program. The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member (Tier 1 or Tier 2) or at NIIMBL’s Headquarters (NIIMBL HQ) in Delaware to support NIIMBL-led projects.
The NIIMBL Faculty Fellows program closes December 31, 2024.
RFP: Project Call 9.1
Concept submissions for Project Call 9.1 are now closed.
NIIMBL is pleased to announce Project Call 9.1, with member- driven and industry-led priority topic areas for technical development proposals.
Technology Topics:
Workforce Development Topics
Our members are stakeholders from across the biopharmaceutical manufacturing ecosystem, including large and small companies, academic institutions, and nonprofits.
Members have the opportunity to collectively revolutionize current biomanufacturing platforms, processes, and educational programs and share in the benefits of these transformative solutions.
The NIIMBL ecosystem’s collaborative efforts to accelerate innovative manufacturing technologies help to:
Biopharmaceuticals are medicines and medical countermeasures that save, sustain, and improve lives. They:
Mike Kress, Sr. Vice President Development Sciences and Clinical Supply,
Merck & Co., Inc.
We offer a variety of membership options that give you the flexibility to choose your organization’s level of engagement based on technology interests and priorities.
